Literature DB >> 8923050

A standard immunoglobulin preparation produced from bovine colostra shows antibody reactivity and neutralization activity against Shiga-like toxins and EHEC-hemolysin of Escherichia coli O157:H7.

R Lissner1, H Schmidit, H Karch.   

Abstract

Enterohemorrhagic Escherichia coli (EHEC) causes a variety of clinical conditions, the most important being hemorrhagic colitis and hemolytic uremic syndrome. A curative therapy of EHEC diseases is not yet feasible. This study investigates the antibody reactivity of Lactobin, a standardized immunoglobulin (Ig) preparation, obtained from the colostra of non-immunized cows. Three different batches of Lactobin exhibited equally high titers of specific antibodies against Shiga-like toxins (SLTs, verocytotoxins) and EHEC hemolysin (EHEC-Hly) produced by E. coli O157. In addition, Lactobin blocked the cytotoxic effect of SLT-I and SLT-II on Vero cell monolayers and inhibited the cytolytic effects of EHEC-Hly on human erythrocytes. Since Lactobin contains high levels of antibodies and neutralizing activity against important virulence factors of EHEC O157, this drug has potential use in the treatment of diarrhea and the prevention of EHEC-associated hemolytic uremic syndrome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8923050     DOI: 10.1007/bf01716084

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  32 in total

1.  Detection and characterization of fecal verotoxin-producing Escherichia coli from healthy cattle.

Authors:  M A Montenegro; M Bülte; T Trumpf; S Aleksić; G Reuter; E Bulling; R Helmuth
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

2.  Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls.

Authors:  M Bitzan; M Klemt; R Steffens; D E Müller-Wiefel
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

3.  Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients.

Authors:  J Nord; P Ma; D DiJohn; S Tzipori; C O Tacket
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

4.  Infections with Escherichia coli O157:H7 in Washington State. The first year of statewide disease surveillance.

Authors:  S M Ostroff; J M Kobayashi; J H Lewis
Journal:  JAMA       Date:  1989-07-21       Impact factor: 56.272

5.  Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences.

Authors:  G D Armstrong; E Fodor; R Vanmaele
Journal:  J Infect Dis       Date:  1991-12       Impact factor: 5.226

6.  The role of Escherichia coli O 157 infections in the classical (enteropathic) haemolytic uraemic syndrome: results of a Central European, multicentre study.

Authors:  M Bitzan; K Ludwig; M Klemt; H König; J Büren; D E Müller-Wiefel
Journal:  Epidemiol Infect       Date:  1993-04       Impact factor: 2.451

7.  Expression of A and B subunits of Shiga-like toxin II as fusions with glutathione S-transferase and their potential for use in seroepidemiology.

Authors:  F Gunzer; H Karch
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

8.  Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli.

Authors:  C O Tacket; G Losonsky; H Link; Y Hoang; P Guesry; H Hilpert; M M Levine
Journal:  N Engl J Med       Date:  1988-05-12       Impact factor: 91.245

9.  Reproduction of edema disease of swine with purified Shiga-like toxin-II variant.

Authors:  D L MacLeod; C L Gyles; B P Wilcock
Journal:  Vet Pathol       Date:  1991-01       Impact factor: 2.221

10.  A comparison of immunomagnetic separation and direct culture for the isolation of verocytotoxin-producing Escherichia coli O157 from bovine faeces.

Authors:  P A Chapman; D J Wright; C A Siddons
Journal:  J Med Microbiol       Date:  1994-06       Impact factor: 2.472

View more
  12 in total

1.  Antibacterial agents and release of periplasmic pertussis toxin from Bordetella pertussis.

Authors:  K A Craig-Mylius; A A Weiss
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 2.  Passive immunity against human pathogens using bovine antibodies.

Authors:  C Weiner; Q Pan; M Hurtig; T Borén; E Bostwick; L Hammarström
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

3.  Antibodies against spike protein of SARS-CoV-2 variants in bovine whey IgG enriched fraction.

Authors:  Satoshi Oshiro; Naeko Mizutani; Tatsuya Tada; Jun-Ichiro Sekiguchi; Masao Takahashi; Teruo Kirikae
Journal:  Int Dairy J       Date:  2022-06-10       Impact factor: 3.572

4.  Bovine colostrum contains immunoglobulin G antibodies against intimin, EspA, and EspB and inhibits hemolytic activity mediated by the type three secretion system of attaching and effacing Escherichia coli.

Authors:  Daniel A Vilte; Mariano Larzábal; Angel A Cataldi; Elsa C Mercado
Journal:  Clin Vaccine Immunol       Date:  2008-06-18

5.  Bovine colostral antibody against verotoxin 2 derived from Escherichia coli O157:H7: resistance to proteases and effects in beagle dogs.

Authors:  Takashi Kuribayashi; Tetsuro Seita; Mariko Matsumoto; Katsunori Furuhata; Kazutoshi Tagata; Shizuo Yamamoto
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

6.  Role of colostrum in gastrointestinal infections.

Authors:  Pawan Rawal; Vineet Gupta; B R Thapa
Journal:  Indian J Pediatr       Date:  2008-09       Impact factor: 1.967

7.  Immunoglobulin G from bovine milk primes intestinal epithelial cells for increased colonization of bifidobacteria.

Authors:  Sinead T Morrin; Geoffrey McCarthy; Deirdre Kennedy; Mariarosaria Marotta; Jane A Irwin; Rita M Hickey
Journal:  AMB Express       Date:  2020-06-18       Impact factor: 3.298

Review 8.  Effects of Bovine Immunoglobulins on Immune Function, Allergy, and Infection.

Authors:  Laurien H Ulfman; Jeanette H W Leusen; Huub F J Savelkoul; John O Warner; R J Joost van Neerven
Journal:  Front Nutr       Date:  2018-06-22

9.  Enriched bovine IgG fraction prevents infections with Enterohaemorrhagic Escherichia coli O157:H7, Salmonella enterica serovar Enteritidis, and Mycobacterium avium.

Authors:  Keiji Funatogawa; Tatsuya Tada; Kyoko Kuwahara-Arai; Teruo Kirikae; Masao Takahashi
Journal:  Food Sci Nutr       Date:  2019-07-17       Impact factor: 2.863

10.  Bovine colostrum in oral treatment of enterogenic endotoxaemia in rats.

Authors:  J Rüdiger Döhler; Lars Nebermann
Journal:  Crit Care       Date:  2002-09-25       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.